Loading clinical trials...
Loading clinical trials...
Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance
Conditions
Interventions
peripheral blood progenitor cells carrying MDR1
Locations
1
United States
National Cancer Institute (NCI)
Bethesda, Maryland, United States
Start Date
October 1, 1995
Completion Date
June 1, 2000
Last Updated
March 4, 2008
NCT07213804
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07046923
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions